Peptide therapeutics market is expected to grow over the forecast
period owing to the increasing prevalence of cancer and other various
metabolic diseases. The other growth drivers of this market are
introduction of technological advancements such as hybrid method of
synthesis of peptides, lifestyle induced diseases such as obesity &
diabetes, sophisticated healthcare infrastructure, increasing population
and awareness.
Peptides are referred as amide bonds which are linked with small
chains of amino acid monomers. Peptides differ from protein on the basis
of size. The presence of amino acids in peptides is less than 55
molecules. Peptides crunch themselves to some imitate such as receptor
ligands and specific cell surface receptors. As peptides act on cell
membrane, so it helps peptides in treating various diseases.
Browse Detail Report With TOC @ http://www.hexaresearch.com/research-report/peptide-therapeutics-industry/
As the market has a huge potential, thus various biotechnology and
pharmaceutical industries are developing new peptides that can be used
for various purposes. So these companies are actively investing in high
R&D activities. Globally, cancer has been a foremost cause of death.
As per the recent report published by WHO, it says that as of 2012,
total number of cancer patient increased to 12.9 million and it is
expected to be 16.2 million over the forecast period.
Peptide therapeutics market is expected to boost owing to rise in
metabolic diseases such as obesity & diabetes and further with
growth in number of cancer patients. Various routes of administration
and technologies in peptides have developed due to continuous R&D.
In 2103, parenteral route of peptides has captured highest revenue
share. Parenteral route is one of the conventional routes of
administration. In 2013, long phase peptide synthesis has dominated the
technology phase. The market serves the huge opportunity over the
upcoming five years.
Technology Insight
Peptide therapeutics market is segmented on the basis of technology
into HPPS, LPPS and SPPS. Among these SPPS technology held the largest
market share in 2013 due to user friendliness and cost effective. In
recent years HPSS technology has generated huge momentum and it is
expected to be fastest growing technology over the forecast period.
Application Insights
Peptide therapeutics market is segmented on the basis of application
into metabolic, cancer, CNS and CVS. In 2013, Peptide therapeutics had
occupied most of the market share as it is used for treatment of cancer.
Growing incidences of cancer and awareness is expected to drive the
market over the forecast period.
Request A Sample copy of This Report @ http://www.hexaresearch.com/sample/169
Segment (Route of Administration) Insight
Peptide therapeutics market is segmented on the basis route of
administration into oral, parenteral, mucosal and pulmonary. Among these
parenteral routes held the largest market share in 2013, as it is used
for a long time. Over the upcoming five years higher comfort level of
patients is expected to drive the parenteral route.
Product Insight
Peptide therapeutics market is segmented on the basis product types
into generic and innovative. Among these, innovative peptides held the
largest market share in 2013, as it is cost effective as compared to
generic peptides. With the help of technological advancement it is
expected to grow over the forecast period.
Regional Insights
Geographically, the Peptide therapeutics market is studied by
segmenting the market into North America, Europe, Asia Pacific and RoW.
North America is dominating the whole market due to high per capita
healthcare expenditure, sophisticated healthcare infrastructure, rising
disposable income, various government or NGO’s initiatives and
increasing geriatric population. Asia Pacific is expected to witness
lucrative growth rate over the forecast period due to increasing
population, government initiatives and growing economies.
Competitive Insights
The major market players in the Peptide therapeutics market are
Bristol-Myers Squibb (BMS), Amylin Pharmaceuticals LLC, Bachem Holding
AG, Roche, Amgen Inc., Peptisyntha, Ipsen, Eli Lilly and Company,
AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Merck & Co.,
Lonza Inc., Novartis AG, GlaxoSmithKline (GSK), PolyPeptide Group,
Novo-Nordisk A/S, Pfizer Inc., Sanofi, and Teva Pharmaceuticals.
Browse Full Report @ http://www.hexaresearch.com/research-report/peptide-therapeutics-industry/
About Us:
Hexa Research is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit our Blog: http://2015hexaresearchpapers.blogspot.com/
No comments:
Post a Comment